- Home
- IMCC vs NLSP Comparison
IMCC vs NLSP Comparison
Compare IMCC & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCC
- NLSP
- Stock Information
- Founded
- IMCC 1980
- NLSP 2015
- Country
- IMCC Israel
- NLSP Switzerland
- Employees
- IMCC N/A
- NLSP N/A
- Industry
- IMCC Medicinal Chemicals and Botanical Products
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- IMCC Health Care
- NLSP Health Care
- Exchange
- IMCC Nasdaq
- NLSP Nasdaq
- Market Cap
- IMCC 7.5M
- NLSP 6.2M
- IPO Year
- IMCC N/A
- NLSP 2021
- Fundamental
- Price
- IMCC $2.16
- NLSP $1.95
- Analyst Decision
- IMCC
- NLSP
- Analyst Count
- IMCC 0
- NLSP 0
- Target Price
- IMCC N/A
- NLSP N/A
- AVG Volume (30 Days)
- IMCC 11.3K
- NLSP 6.1M
- Earning Date
- IMCC 03-27-2025
- NLSP 10-18-2024
- Dividend Yield
- IMCC N/A
- NLSP N/A
- EPS Growth
- IMCC N/A
- NLSP N/A
- EPS
- IMCC N/A
- NLSP N/A
- Revenue
- IMCC $38,042,859.00
- NLSP N/A
- Revenue This Year
- IMCC $22.59
- NLSP N/A
- Revenue Next Year
- IMCC $32.86
- NLSP N/A
- P/E Ratio
- IMCC N/A
- NLSP N/A
- Revenue Growth
- IMCC N/A
- NLSP N/A
- 52 Week Low
- IMCC $1.61
- NLSP $1.71
- 52 Week High
- IMCC $8.10
- NLSP $18.40
- Technical
- Relative Strength Index (RSI)
- IMCC 44.61
- NLSP 44.06
- Support Level
- IMCC $2.11
- NLSP $2.14
- Resistance Level
- IMCC $2.33
- NLSP $2.34
- Average True Range (ATR)
- IMCC 0.16
- NLSP 0.24
- MACD
- IMCC 0.00
- NLSP -0.00
- Stochastic Oscillator
- IMCC 20.00
- NLSP 12.07
About IMCC IM Cannabis Corp.
IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.